Roche ’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
ALINA data demonstrateAlecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cureThese data will be submitted to health authorities globallyand presented at an upcoming medical meetingBasel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecens...
Source: Roche Media News - September 1, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
ALINA data demonstrateAlecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cureThese data will be submitted to health authorities globallyand presented at an upcoming medical meetingBasel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecens...
Source: Roche Investor Update - September 1, 2023 Category: Pharmaceuticals Source Type: news
Advancements of ALK Inhibition of NSCLC Advancements of ALK Inhibition of NSCLC
Due to ongoing advancements, the treatment landscape for NSCLC continues to evolve. This review looks at recent developments in ALK-targeting therapies.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Types
(MedPage Today) -- A new-generation KRAS G12C inhibitor induced responses in more than half of patients with previously treated non-small cell lung cancer (NSCLC) harboring the mutation, a subgroup analysis of a phase I trial showed.
In 58 patients... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 24, 2023 Category: Gastroenterology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
Basel, 23 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators. We are continuing the study until the final analysis for overall survival. All other stud...
Source: Roche Media News - August 23, 2023 Category: Pharmaceuticals Source Type: news
Roche posts interim OS data from PhIII TIGIT trial after leak
Roche has posted a snapshot from a closely-watched Phase III trial of its TIGIT antibody after an “inadvertent disclosure.” Although the overall survival data are still not mature, analysts believe the numbers so far point to a positive trend in non-small cell lung cancer.…#roche #unlock (Source: Reuters: Health)
Source: Reuters: Health - August 23, 2023 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
Basel, 23 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators. We are continuing the study until the final analysis for overall survival. All other stud...
Source: Roche Investor Update - August 23, 2023 Category: Pharmaceuticals Source Type: news
Drug Trials Snapshot: EXKIVITY
EXKIVITY is a kinase inhibitor used to treat adult patients with a type of lung cancer (non-small cell lung cancer or NSCLC) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Atezolizumab Monotherapy Beneficial for NSCLC Ineligible for Platinum-Based Chemo
TUESDAY, Aug. 15, 2023 -- For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 15, 2023 Category: Pharmaceuticals Source Type: news
FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 9, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Grants Regular Approval for Gavreto (pralsetinib) for Non-Small Cell Lung Cancer with RET Gene Fusions
On August 9, 2023, the Food and Drug Administration granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 9, 2023 Category: Drugs & Pharmacology Source Type: news
First-Line Afatinib in EGFR NSCLC Patients With Brain Mets First-Line Afatinib in EGFR NSCLC Patients With Brain Mets
A new study looks at the effectiveness of first-line afatinib for patients with EGFR-mutated NSCLC and brain metastasis in a real-world setting.Translational Lung Cancer Research (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 7, 2023 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news
For NSCLC, Neoadjuvant, Adjuvant, or Both? For NSCLC, Neoadjuvant, Adjuvant, or Both?
H. Jack West, MD, and Julia Rotow, MD, discuss data on perioperative approaches presented at ASCO 2023.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 4, 2023 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
